ArticleThe Journal of pathology2020

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Ilaria Alborelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.